2024
1. Synthetic Lethality Beyond BRCA: A Phase I Study of Rucaparib and Irinotecan in Metastatic Solid Tumors With Homologous Recombination-Deficiency Mutations Beyond BRCA1/2. Tsang, E. S.; Dhawan, M. S.; Pacaud, R.; Thomas, S.; Grabowsky, J.; Wilch, L.; Karipineni, S.; Kelley, R. K.; Ko, A. H.; Collisson, E.; Chapman, J. S.; Ueda, S.; Bergsland, E. K.; Munster, P. JCO Precis Oncol 2024, 8, e2300494. https://doi.org/10.1200/PO.23.00494.
2. Combination of Itacitinib or Parsaclisib with Pembrolizumab in Patients with Advanced Solid Tumors: A Phase I Study. Munster, P.; Iannotti, N.; Cho, D. C.; Kirkwood, J. M.; Villaruz, L. C.; Gibney, G. T.; Hodi, F. S.; Mettu, N. B.; Jones, M.; Bowman, J.; Smith, M.; Lakshminarayanan, M.; O’Day, S. Cancer Res Commun 2024, 4 (3), 785. https://doi.org/10.1158/2767-9764.CRC-24-0133.
3. A Phase II Trial of the WEE1 Inhibitor Adavosertib in SETD2-Altered Advanced Solid Tumor Malignancies (NCI 10170). Maldonado, E.; Rathmell, W. K.; Shapiro, G. I.; Takebe, N.; Rodon, J.; Mahalingam, D.; Trikalinos, N. A.; Kalebasty, A. R.; Parikh, M.; Boerner, S. A.; Balido, C.; Krings, G.; Burns, T. F.; Bergsland, E. K.; Munster, P. N.; Ashworth, A.; LoRusso, P.; Aggarwal, R. R. Cancer Res Commun 2024, 4 (7), 1793–1801. https://doi.org/10.1158/2767-9764.CRC-24-0213.
4. ORIC-101, a Glucocorticoid Receptor Antagonist, in Combination with Nab-Paclitaxel in Patients with Advanced Solid Tumors. Chen, C. T.; Khanna, V.; Kummar, S.; Abdul-Karim, R. M.; Sommerhalder, D.; Tolcher, A. W.; Ueno, N. T.; Davis, S. L.; Orr, D. W.; Hamilton, E.; Patel, M. R.; Spira, A. I.; Jauhari, S.; Florou, V.; Duff, M.; Xu, R.; Wang, J.; Barkund, S. R.; Zhou, H.; Pankov, A.; Kong, W.; Jahchan, N. S.; Jackson, E. L.; Sun, J. D.; Junttila, M. R.; Multani, P. S.; Daemen, A.; Chow Maneval, E.; Munster, P. N. Cancer Res Commun 2024. https://doi.org/10.1158/2767-9764.CRC-24-0115.
5. Phase I Study of Elraglusib (9-ING-41), a Glycogen Synthase Kinase-3β Inhibitor, as Monotherapy or Combined with Chemotherapy in Patients with Advanced Malignancies. Carneiro, B. A.; Cavalcante, L.; Mahalingam, D.; Saeed, A.; Safran, H.; Ma, W. W.; Coveler, A. L.; Powell, S.; Bastos, B.; Davis, E.; Sahai, V.; Mikrut, W.; Longstreth, J.; Smith, S.; Weisskittel, T.; Li, H.; Borden, B. A.; Harvey, R. D.; Sahebjam, S.; Cervantes, A.; Koukol, A.; Mazar, A. P.; Steeghs, N.; Kurzrock, R.; Giles, F. J.; Munster, P. Clin Cancer Res 2024, 30 (3), 522–531. https://doi.org/10.1158/1078-0432.CCR-23-1916.
2023
6. Vaccinia (Smallpox) for the Treatment of Ovarian Cancer-Turning an Old Foe Into a Friend? Tsang, E. S.; Munster, P. N. JAMA Oncol 2023, 9 (7), 894–896. https://doi.org/10.1001/jamaoncol.2023.0983.
7. A Phase 1b/2 Study of Alpelisib in Combination with Cetuximab in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.Razak, A. R. A.; Wang, H.-M.; Chang, J.-Y.; Ahn, M.-J.; Munster, P.; Blumenschein, G.; Solomon, B.; Lim, D. W.-T.; Hong, R.-L.; Pfister, D.; Saba, N. F.; Lee, S.-H.; van Herpen, C.; Quadt, C.; Bootle, D.; Blumenstein, L.; Demanse, D.; Delord, J.-P. Target Oncol 2023, 18 (6), 853–868. https://doi.org/10.1007/s11523-023-00997-z.
8. Combination of Itacitinib or Parsaclisib with Pembrolizumab in Patients with Advanced Solid Tumors: A Phase I Study. Munster, P.; Iannotti, N.; Cho, D. C.; Kirkwood, J. M.; Villaruz, L. C.; Gibney, G. T.; Hodi, F. S.; Mettu, N. B.; Jones, M.; Bowman, J.; Smith, M.; Lakshminarayanan, M.; O’Day, S. Cancer Res Commun 2023, 3 (12), 2572–2584. https://doi.org/10.1158/2767-9764.CRC-22-0461.
9. ATM-SPARK: A GFP Phase Separation-Based Activity Reporter of ATM. Li, X.; Chung, C.-I.; Yang, J.; Chaudhuri, S.; Munster, P. N.; Shu, X. Sci Adv 2023, 9 (9), eade3760. https://doi.org/10.1126/sciadv.ade3760.
2022
10. A Phase IB Trial of the PI3K Inhibitor Alpelisib and Weekly Cisplatin in Patients with Solid Tumor Malignancies. Tsang, E. S.; Aggarwal, R. R.; Dhawan, M. S.; Bergsland, E. K.; Alvarez, E. A.; Calabrese, S.; Pacaud, R.; Garcia, J.; Fattah, D.; Thomas, S.; Grabowsky, J.; Moasser, M. M.; Munster, P. N. Cancer Research Communications 2022, 2 (7), 570–576. https://doi.org/10.1158/2767-9764.CRC-22-0028.
11. Targeting RAD51-Mediated Homologous Recombination as a Treatment for Advanced Solid and Hematologic Malignancies: Opportunities and Challenges Ahead. Tsang, E. S.; Munster, P. N. OTT 2022, Volume 15, 1509–1518. https://doi.org/10.2147/OTT.S322297.
12. Overcoming Taxane Resistance: Preclinical and Phase 1 Studies of Relacorilant, a Selective Glucocorticoid Receptor Modulator, with Nab-Paclitaxel in Solid Tumors. Munster, P. N.; Greenstein, A. E.; Fleming, G. F.; Borazanci, E.; Sharma, M. R.; Custodio, J. M.; Tudor, I. C.; Pashova, H. I.; Shepherd, S. P.; Grauer, A.; Sachdev, J. C. Clinical Cancer Research 2022, 28 (15), 3214–3224. https://doi.org/10.1158/1078-0432.CCR-21-4363.
2021
13. Immunotherapy in Breast Cancer: A Clinician’s Perspective. Chaudhuri, S.; Thomas, S.; Munster, P. Journal of the National Cancer Center 2021, 1 (2), 47–57. https://doi.org/10.1016/j.jncc.2021.01.001.
2020
14. Exhausted T Cell Signature Predicts Immunotherapy Response in ER-Positive Breast Cancer. Terranova-Barberio, M.; Pawlowska, N.; Dhawan, M.; Moasser, M.; Chien, A. J.; Melisko, M. E.; Rugo, H.; Rahimi, R.; Deal, T.; Daud, A.; Rosenblum, M. D.; Thomas, S.; Munster, P. N. Nat Commun 2020, 11 (1), 3584. https://doi.org/10.1038/s41467-020-17414-y.
2019
15. Histone Deacetylase Inhibition with Panobinostat Combined with Intensive Induction Chemotherapy in Older Patients with Acute Myeloid Leukemia: Phase I Study Results. Wieduwilt, M. J.; Pawlowska, N.; Thomas, S.; Olin, R.; Logan, A. C.; Damon, L. E.; Martin, T.; Kang, M.; Sayre, P. H.; Boyer, W.; Gaensler, K. M. L.; Anderson, K.; Munster, P. N.; Andreadis, C. Clinical Cancer Research 2019, 25 (16), 4917–4923. https://doi.org/10.1158/1078-0432.CCR-19-0171.
16. First-In-Human Phase I Study Of A Dual mTOR Kinase And DNA-PK Inhibitor (CC-115) In Advanced Malignancy. Munster, P.; Mita, M.; Mahipal, A.; Nemunaitis, J.; Massard, C.; Mikkelsen, T.; Cruz, C.; Paz-Ares, L.; Hidalgo, M.; Rathkopf, D.; Blumenschein Jr, G.; Smith, D. C.; Eichhorst, B.; Cloughesy, T.; Filvaroff, E. H.; Li, S.; Raymon, H.; De Haan, H.; Hege, K.; Bendell, J. C. CMAR 2019, Volume 11, 10463–10476. https://doi.org/10.2147/CMAR.S208720.
17. Single-Arm Phases 1 and 2 Trial of Niraparib in Combination With Pembrolizumab in Patients With Recurrent Platinum-Resistant Ovarian Carcinoma. Konstantinopoulos, P. A.; Waggoner, S.; Vidal, G. A.; Mita, M.; Moroney, J. W.; Holloway, R.; Van Le, L.; Sachdev, J. C.; Chapman-Davis, E.; Colon-Otero, G.; Penson, R. T.; Matulonis, U. A.; Kim, Y. B.; Moore, K. N.; Swisher, E. M.; Färkkilä, A.; D’Andrea, A.; Stringer-Reasor, E.; Wang, J.; Buerstatte, N.; Arora, S.; Graham, J. R.; Bobilev, D.; Dezube, B. J.; Munster, P. JAMA Oncol 2019, 5 (8), 1141. https://doi.org/10.1001/jamaoncol.2019.1048.
18. Randomized Trial of Lisinopril Versus Carvedilol to Prevent Trastuzumab Cardiotoxicity in Patients With Breast Cancer. Guglin, M.; Krischer, J.; Tamura, R.; Fink, A.; Bello-Matricaria, L.; McCaskill-Stevens, W.; Munster, P. N. Journal of the American College of Cardiology 2019, 73 (22), 2859–2868. https://doi.org/10.1016/j.jacc.2019.03.495.
2018
19. Local Delivery of Hormonal Therapy with Silastic Tubing for Prevention and Treatment of Breast Cancer. Park, J.; Thomas, S.; Zhong, A. Y.; Wolfe, A. R.; Krings, G.; Terranova-Barberio, M.; Pawlowska, N.; Benet, L. Z.; Munster, P. N. Sci Rep 2018, 8 (1), 92. https://doi.org/10.1038/s41598-017-18436-1.
20. Safety and Pharmacokinetics of MM-302, a HER2-Targeted Antibody–Liposomal Doxorubicin Conjugate, in Patients with Advanced HER2-Positive Breast Cancer: A Phase 1 Dose-Escalation Study. Munster, P.; Krop, I. E.; LoRusso, P.; Ma, C.; Siegel, B. A.; Shields, A. F.; Molnár, I.; Wickham, T. J.; Reynolds, J.; Campbell, K.; Hendriks, B. S.; Adiwijaya, B. S.; Geretti, E.; Moyo, V.; Miller, K. D. Br J Cancer 2018, 119 (9), 1086–1093. https://doi.org/10.1038/s41416-018-0235-2.
21. A Phase I Dose-Escalation and Dose-Expansion Study of Brontictuzumab in Subjects with Selected Solid Tumors. Ferrarotto, R.; Eckhardt, G.; Patnaik, A.; LoRusso, P.; Faoro, L.; Heymach, J. V.; Kapoun, A. M.; Xu, L.; Munster, P. Annals of Oncology 2018, 29 (7), 1561–1568. https://doi.org/10.1093/annonc/mdy171.
2017
22. Autologous Fat Grafting as a Novel Antiestrogen Vehicle for the Treatment of Breast Cancer. Thomas, S.; Chen, S.; Sbitany, H.; Kwon, E.; Piper, M.; Park, J.; Terranova Barberio, M.; Pawlowska, N.; Munster, P. N. Plastic & Reconstructive Surgery 2017, 140 (3), 537–544. https://doi.org/10.1097/PRS.0000000000003579.
23. Host Histone Acetylation Unlocks HDAC Inhibitor Potential. Terranova-Barberio, M.; Thomas, S.; Munster, P. N. Oncotarget 2017, 8 (63), 106161–106162. https://doi.org/10.18632/oncotarget.22422.
24. HDAC Inhibition Potentiates Immunotherapy in Triple Negative Breast Cancer. Terranova-Barberio, M.; Thomas, S.; Ali, N.; Pawlowska, N.; Park, J.; Krings, G.; Rosenblum, M. D.; Budillon, A.; Munster, P. N. Oncotarget 2017, 8 (69), 114156–114172. https://doi.org/10.18632/oncotarget.23169.
25. Differential Toxicity in Patients with and without DNA Repair Mutations: Phase I Study of Carboplatin and Talazoparib in Advanced Solid Tumors. Dhawan, M. S.; Bartelink, I. H.; Aggarwal, R. R.; Leng, J.; Zhang, J. Z.; Pawlowska, N.; Terranova-Barberio, M.; Grabowsky, J. A.; Gewitz, A.; Chien, A. J.; Moasser, M.; Kelley, R. K.; Maktabi, T.; Thomas, S.; Munster, P. N. Clinical Cancer Research 2017, 23 (21), 6400–6410. https://doi.org/10.1158/1078-0432.CCR-17-0703.
26. Heterogeneous Drug Penetrance of Veliparib and Carboplatin Measured in Triple Negative Breast Tumors. Bartelink, I. H.; Prideaux, B.; Krings, G.; Wilmes, L.; Lee, P. R. E.; Bo, P.; Hann, B.; Coppé, J.-P.; Heditsian, D.; Swigart-Brown, L.; Jones, E. F.; Magnitsky, S.; Keizer, R. J.; De Vries, N.; Rosing, H.; Pawlowska, N.; Thomas, S.; Dhawan, M.; Aggarwal, R.; Munster, P. N.; Esserman, L. J.; Ruan, W.; Wu, A. H. B.; Yee, D.; Dartois, V.; Savic, R. M.; Wolf, D. M.; Van ’T Veer, L. Breast Cancer Res 2017, 19 (1), 107. https://doi.org/10.1186/s13058-017-0896-4.
27. Inhibiting Histone Deacetylase as a Means to Reverse Resistance to Angiogenesis Inhibitors: Phase I Study of Abexinostat Plus Pazopanib in Advanced Solid Tumor Malignancies. Aggarwal, R.; Thomas, S.; Pawlowska, N.; Bartelink, I.; Grabowsky, J.; Jahan, T.; Cripps, A.; Harb, A.; Leng, J.; Reinert, A.; Mastroserio, I.; Truong, T.-G.; Ryan, C. J.; Munster, P. N. JCO 2017, 35 (11), 1231–1239. https://doi.org/10.1200/JCO.2016.70.5350.
2016
28. A Phase I Trial of Panobinostat and Epirubicin in Solid Tumors with a Dose Expansion in Patients with Sarcoma. Thomas, S.; Aggarwal, R.; Jahan, T.; Ryan, C.; Troung, T.; Cripps, A. M.; Raha, P.; Thurn, K. T.; Chen, S.; Grabowsky, J. A.; Park, J.; Hwang, J.; Daud, A.; Munster, P. N. Annals of Oncology 2016, 27 (5), 947–952. https://doi.org/10.1093/annonc/mdw044.
29. Epigenetic Modifiers in Immunotherapy: A Focus on Checkpoint Inhibitors. Terranova-Barberio, M.; Thomas, S.; Munster, P. N. Immunotherapy 2016, 8 (6), 705–719. https://doi.org/10.2217/imt-2016-0014.
30. Effect of Temporary Ovarian Suppression on Chemotherapy-Induced Amenorrhea, Pregnancy, and Outcome. Munster, P. N. JAMA Oncol 2016, 2 (8), 1089. https://doi.org/10.1001/jamaoncol.2016.0614.
31. First-in-Human Phase I Study of GSK2126458, an Oral Pan-Class I Phosphatidylinositol-3-Kinase Inhibitor, in Patients with Advanced Solid Tumor Malignancies. Munster, P.; Aggarwal, R.; Hong, D.; Schellens, J. H. M.; Van Der Noll, R.; Specht, J.; Witteveen, P. O.; Werner, T. L.; Dees, E. C.; Bergsland, E.; Agarwal, N.; Kleha, J. F.; Durante, M.; Adams, L.; Smith, D. A.; Lampkin, T. A.; Morris, S. R.; Kurzrock, R. Clinical Cancer Research 2016, 22 (8), 1932–1939. https://doi.org/10.1158/1078-0432.CCR-15-1665.
32. A Phase 1b Study of the Akt-Inhibitor MK-2206 in Combination with Weekly Paclitaxel and Trastuzumab in Patients with Advanced HER2-Amplified Solid Tumor Malignancies. Chien, A. J.; Cockerill, A.; Fancourt, C.; Schmidt, E.; Moasser, M. M.; Rugo, H. S.; Melisko, M. E.; Ko, A. H.; Kelley, R. K.; Korn, W. M.; Esserman, L. J.; Van‘T Veer, L.; Yau, C.; Wolf, D. M.; Munster, P. N. Breast Cancer Res Treat 2016, 155 (3), 521–530. https://doi.org/10.1007/s10549-016-3701-7.
2015
33. Combined Histone Deacetylase Inhibition and Tamoxifen Induces Apoptosis in Tamoxifen-Resistant Breast Cancer Models, by Reversing Bcl-2 Overexpression. Raha, P.; Thomas, S.; Thurn, K. T.; Park, J.; Munster, P. N. Breast Cancer Res 2015, 17 (1), 26. https://doi.org/10.1186/s13058-015-0533-z.
34. Epigenetic Modulation with Histone Deacetylase Inhibitors in Combination with Immunotherapy. Park, J.; Thomas, S.; Munster, P. N. Epigenomics 2015, 7 (4), 641–652. https://doi.org/10.2217/epi.15.16.
35. Ovarian Protection during Adjuvant Chemotherapy. Oktay, K.; Rodriguez-Wallberg, K.; Munster, P. N Engl J Med 2015, 372 (23), 2268–2270. https://doi.org/10.1056/NEJMc1504241.
36. More Options for Fertility Preservation for Patients With Cancer. Munster, P. N. JCO 2015, 33 (22), 2413–2415. https://doi.org/10.1200/JCO.2015.61.9304.
37. Phase I Dose-Escalation Trial of Checkpoint Kinase 1 Inhibitor MK-8776 As Monotherapy and in Combination With Gemcitabine in Patients With Advanced Solid Tumors. Daud, A. I.; Ashworth, M. T.; Strosberg, J.; Goldman, J. W.; Mendelson, D.; Springett, G.; Venook, A. P.; Loechner, S.; Rosen, L. S.; Shanahan, F.; Parry, D.; Shumway, S.; Grabowsky, J. A.; Freshwater, T.; Sorge, C.; Kang, S. P.; Isaacs, R.; Munster, P. N. JCO 2015, 33 (9), 1060–1066. https://doi.org/10.1200/JCO.2014.57.5027.
38. A Phase I Dose‐escalation Study to Assess Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of the Dual mTORC1/mTORC2 Kinase Inhibitor CC‐223 in Patients with Advanced Solid Tumors or Multiple Myeloma. Bendell, J. C.; Kelley, R. K.; Shih, K. C.; Grabowsky, J. A.; Bergsland, E.; Jones, S.; Martin, T.; Infante, J. R.; Mischel, P. S.; Matsutani, T.; Xu, S.; Wong, L.; Liu, Y.; Wu, X.; Mortensen, D. S.; Chopra, R.; Hege, K.; Munster, P. N. Cancer 2015, 121 (19), 3481–3490. https://doi.org/10.1002/cncr.29422.
2014
39. New Protein Kinase Inhibitors in Breast Cancer: Afatinib and Neratinib. Zhang, X.; Munster, P. N. Expert Opinion on Pharmacotherapy 2014, 15 (9), 1277–1288. https://doi.org/10.1517/14656566.2014.913570.
40. Impact of Patient Ethnicity on the Metabolic and Immunologic Effects of PI3K–mTOR Pathway Inhibition in Patients with Solid Tumor Malignancies. Aggarwal, R.; Grabowsky, J.; Strait, N.; Cockerill, A.; Munster, P. Cancer Chemother Pharmacol 2014, 74 (2), 359–365. https://doi.org/10.1007/s00280-014-2510-0.
2013
41. Histone Deacetylase Regulation of ATM-Mediated DNA Damage Signaling. Thurn, K. T.; Thomas, S.; Raha, P.; Qureshi, I.; Munster, P. N. Molecular Cancer Therapeutics 2013, 12 (10), 2078–2087. https://doi.org/10.1158/1535-7163.MCT-12-1242.
42. Efficacy of Histone Deacetylase and Estrogen Receptor Inhibition in Breast Cancer Cells Due to Concerted down Regulation of Akt. Thomas, S.; Thurn, K. T.; Raha, P.; Chen, S.; Munster, P. N. PLoS One 2013, 8 (7), e68973. https://doi.org/10.1371/journal.pone.0068973.
43. Fertility Preservation and Breast Cancer: A Complex Problem. Munster, P. N. Oncology (Williston Park) 2013, 27 (6), 533–539.
2012
44. Randomized Trial Using Gonadotropin-Releasing Hormone Agonist Triptorelin for the Preservation of Ovarian Function during (Neo)Adjuvant Chemotherapy for Breast Cancer. Munster, P. N.; Moore, A. P.; Ismail-Khan, R.; Cox, C. E.; Lacevic, M.; Gross-King, M.; Xu, P.; Carter, W. B.; Minton, S. E. J Clin Oncol 2012, 30 (5), 533–538. https://doi.org/10.1200/JCO.2011.34.6890.
2011
45. Rational Therapeutic Combinations with Histone Deacetylase Inhibitors for the Treatment of Cancer. Thurn, K. T.; Thomas, S.; Moore, A.; Munster, P. N. Future Oncol 2011, 7 (2), 263–283. https://doi.org/10.2217/fon.11.2.
46. Addition of a Histone Deacetylase Inhibitor Redirects Tamoxifen-Treated Breast Cancer Cells into Apoptosis, Which Is Opposed by the Induction of Autophagy. Thomas, S.; Thurn, K. T.; Biçaku, E.; Marchion, D. C.; Münster, P. N. Breast Cancer Res Treat 2011, 130 (2), 437–447. https://doi.org/10.1007/s10549-011-1364-y.
47. Epigenetic Modulation: A Novel Therapeutic Target for Overcoming Hormonal Therapy Resistance. Raha, P.; Thomas, S.; Munster, P. N. Epigenomics 2011, 3 (4), 451–470. https://doi.org/10.2217/epi.11.72.
48. Preclinical and Clinical Activity of the Topoisomerase I Inhibitor, Karenitecin, in Melanoma. Munster, P. N.; Daud, A. I. Expert Opin Investig Drugs 2011, 20 (11), 1565–1574. https://doi.org/10.1517/13543784.2011.617740.
49. A Phase II Study of the Histone Deacetylase Inhibitor Vorinostat Combined with Tamoxifen for the Treatment of Patients with Hormone Therapy-Resistant Breast Cancer. Munster, P. N.; Thurn, K. T.; Thomas, S.; Raha, P.; Lacevic, M.; Miller, A.; Melisko, M.; Ismail-Khan, R.; Rugo, H.; Moasser, M.; Minton, S. E. Br J Cancer 2011, 104 (12), 1828–1835. https://doi.org/10.1038/bjc.2011.156.
2009
50. Histone Deacetylase Inhibitor Induced Modulation of Anti-Estrogen Therapy. Thomas, S.; Munster, P. N. Cancer Lett 2009, 280 (2), 184–191. https://doi.org/10.1016/j.canlet.2008.12.026.
51. A Single Supratherapeutic Dose of Vorinostat Does Not Prolong the QTc Interval in Patients with Advanced Cancer. Munster, P. N.; Rubin, E. H.; Van Belle, S.; Friedman, E.; Patterson, J. K.; Van Dyck, K.; Li, X.; Comisar, W.; Chodakewitz, J. A.; Wagner, J. A.; Iwamoto, M. Clinical Cancer Research 2009, 15 (22), 7077–7084. https://doi.org/10.1158/1078-0432.CCR-09-1214.
52. Estradiol in Breast Cancer Treatment: Reviving the Past. Munster, P. N.; Carpenter, J. T. JAMA 2009, 302 (7), 797–798. https://doi.org/10.1001/jama.2009.1223.
53. Clinical and Biological Effects of Valproic Acid as a Histone Deacetylase Inhibitor on Tumor and Surrogate Tissues: Phase I/II Trial of Valproic Acid and Epirubicin/FEC. Munster, P.; Marchion, D.; Bicaku, E.; Lacevic, M.; Kim, J.; Centeno, B.; Daud, A.; Neuger, A.; Minton, S.; Sullivan, D. Clin Cancer Res 2009, 15 (7), 2488–2496. https://doi.org/10.1158/1078-0432.CCR-08-1930.
54. A. Phase I Trial of Vorinostat and Doxorubicin in Solid Tumours: Histone Deacetylase 2 Expression as a Predictive Marker. Munster, P. N.; Marchion, D.; Thomas, S.; Egorin, M.; Minton, S.; Springett, G.; Lee, J.-H.; Simon, G.; Chiappori, A.; Sullivan, D.; Daud, Br J Cancer 2009, 101 (7), 1044–1050. https://doi.org/10.1038/sj.bjc.6605293.
55. HDAC2 Regulates Chromatin Plasticity and Enhances DNA Vulnerability. Marchion, D. C.; Bicaku, E.; Turner, J. G.; Schmitt, M. L.; Morelli, D. R.; Munster, P. N. Mol Cancer Ther 2009, 8 (4), 794–801. https://doi.org/10.1158/1535-7163.MCT-08-0985.
56. Potentiation of a Topoisomerase I Inhibitor, Karenitecin, by the Histone Deacetylase Inhibitor Valproic Acid in Melanoma: Translational and Phase I/II Clinical Trial. Daud, A. I.; Dawson, J.; DeConti, R. C.; Bicaku, E.; Marchion, D.; Bastien, S.; Hausheer, F. A.; Lush, R.; Neuger, A.; Sullivan, D. M.; Munster, P. N. Clin Cancer Res 2009, 15 (7), 2479–2487. https://doi.org/10.1158/1078-0432.CCR-08-1931.
2008
57. Selective Inhibition of Histone Deacetylase 2 Silences Progesterone Receptor-Mediated Signaling. Biçaku, E.; Marchion, D. C.; Schmitt, M. L.; Münster, P. N. Cancer Res 2008, 68 (5), 1513–1519. https://doi.org/10.1158/0008-5472.CAN-07-2822.
2007
58. Development of Histone Deacetylase Inhibitors for Cancer Treatment. Marchion, D.; Münster, P. Expert Rev Anticancer Ther 2007, 7 (4), 583–598. https://doi.org/10.1586/14737140.7.4.583.
2005
59. Synergistic Interaction between Histone Deacetylase and Topoisomerase II Inhibitors Is Mediated through Topoisomerase IIbeta. Marchion, D. C.; Bicaku, E.; Turner, J. G.; Daud, A. I.; Sullivan, D. M.; Munster, P. N. Clin Cancer Res 2005, 11 (23), 8467–8475. https://doi.org/10.1158/1078-0432.CCR-05-1073.
60. Valproic Acid Alters Chromatin Structure by Regulation of Chromatin Modulation Proteins. Marchion, D. C.; Bicaku, E.; Daud, A. I.; Sullivan, D. M.; Munster, P. N. Cancer Res 2005, 65 (9), 3815–3822. https://doi.org/10.1158/0008-5472.CAN-04-2478.
61. In Vivo Synergy between Topoisomerase II and Histone Deacetylase Inhibitors: Predictive Correlates. Marchion, D. C.; Bicaku, E.; Daud, A. I.; Sullivan, D. M.; Munster, P. N. Mol Cancer Ther 2005, 4 (12), 1993–2000. https://doi.org/10.1158/1535-7163.MCT-05-0194.
2004
62. Sequence-Specific Potentiation of Topoisomerase II Inhibitors by the Histone Deacetylase Inhibitor Suberoylanilide Hydroxamic Acid. Marchion, D. C.; Bicaku, E.; Daud, A. I.; Richon, V.; Sullivan, D. M.; Munster, P. N. J Cell Biochem 2004, 92 (2), 223–237. https://doi.org/10.1002/jcb.20045.
